|Description||Ryuvidine, a cell-permeable dioxobenzothiazole compound, is an inhibitor of SETD8 (IC50 = 0.5 µM) that suppresses monomethylation of H4K20 in vitro.1 It less potently inhibits cyclin-dependent kinase 4 (Cdk4; IC50 = 6 µM for Cdk4/cyclin D1).|
|Purity||≥98% by HPLC|
|Synonyms||2-Methyl-5-[(4-methylphenyl)amino]-4,7-benzothiazoledione; Cdk4 Inhibitor III; Cyclic-dependent Kinase 4 Inhibitor III; Ryuvidine; SPS8I2; SPS-8I2; SPS 8I2;|
|Storage||Store in a cool and dry place (or refer to the Certificate of Analysis).|
TG003 is a potent, ATP-competitive inhibitor of Clk-family kinases. TG003 inhibited SF2/ASF-dependent splicing of beta-globin pre-mRNA in vitro by suppression o...
LDC000067 is a highly selective CDK9 inhibitor with IC50 of 44 nM, 55/125/210/ >227/ >227-fold selectivity over CDK2/1/4/6/7.LDC000067 reduces Ser2-P, induces p...
CCT-251921 has been found to be a CDK inhibitor that could be significant in the studies of colorectal cancer.
Palbociclib, also known as PD0332991, is an orally available pyridopyrimidine-derived cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic acti...
BAY 1143572 is a highly selective, potent and orally available inhibitor ofPTEFb/CDK9 and shows convincing anti-tumor activity in multiple xenograft models by t...
BMS-265246 is a potent and selective CDK1/2 inhibitor with IC50 of 6 nM/9 nM. It is 25-fold more selective for CDK1/2 than CDK4.
Purvalanol A is a potent CDK inhibitor, which effectively suppresses Src-mediated transformation by inhibiting both CDKs and c-Src. indicating that the activati...
BS-181 is a highly selective CDK inhibitor for CDK7 with an IC(50) of 21 nmol/L. Testing of other CDKs as well as another 69 kinases showed that BS-181 only inh...